AIM - AIM ImmunoTech gains on data for Ampligen/checkpoint inhibitor combo in cancer

The shares of AIM ImmunoTech (NYSE:AIM) are rising the pre-market Thursday after the immuno-pharma company disclosed a summary of clinical data to back the synergistic effect of its cancer candidate Ampligen with checkpoint blockade therapies. A dsRNA drug, known as rintatolimod, Ampligen, is currently undergoing studies as a potential therapy for cancer. The data highlights that “Ampligen as a single agent therapy, as well as in combination with the latest powerful cancer therapies, has the potential to become a breakthrough therapy for some of the most difficult to treat and deadly cancers,” said Chief Executive Officer of AIM, Thomas Equels. The announcement includes data from an investigator-initiated, Phase 2 trial, in which Ampligen, was tested with checkpoint inhibitor pembrolizumab (Keytruda) and chemoimmunotherapy, cisplatin, in patients with recurrent platinum-sensitive ovarian cancer. The clinical responses included two complete responses (15.4%) and three partial responses (23.1%) among 13 evaluable patients, the company said.

For further details see:

AIM ImmunoTech gains on data for Ampligen/checkpoint inhibitor combo in cancer